IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Sarcoma, Kaposi HIV Infections | Drug: Interferon alfa-2a Drug: Zidovudine Drug: Interferon alfa-n1 | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma |
| Estimated Enrollment: | 56 |
| Study Completion Date: | February 1990 |
AZT has been found to inhibit both the in vitro (in test tube) and cell killing effects of HIV, and both interferons (IFN-A and IFN-A2A) have shown antiviral and antitumor effect in Kaposi's sarcoma. It is reasonable to assume that a synergistic effect and enhanced antitumor response may be seen with combination therapy. A study to evaluate the safety and efficacy of AZT in combination with IFN-A or IFN-A2A is warranted.
Patients are randomized to receive IFN-A or IFN-A2A (given by intramuscular injection) and combined with AZT (taken orally) daily for 8 weeks. Study stops when maximum tolerated dose (MTD) is reached. Two cohorts of 4 patients enter each dose level. Patients do not enter into the next dose level until all patients have completed 3 weeks of treatment. AZT will escalate only if there is no unacceptable toxicity (grade 2 in = or > 3 patients or > grade 2 in any patient), subsequent increases in IFN-A or IFN-A2A will be permitted, but the AZT dose will remain fixed. The MTD for a given IFN-A or IFN-A2A dose level is defined as grade 2 toxicity (grade 3 for hemoglobin, neutrophil count, or SGOT) in 4 of the 6 patients. Patients have blood drawn every week and their general health is evaluated. Pharmacokinetic studies will be done on days 1, 21, and 24. Patients tolerating the combination may be continued on the same dose level for 1 year except if patient has reached complete remission for = or > 90 days, IFN-A or IFN-A2A will decrease to 3 times a week.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Patients must have biopsy-proven AIDS-associated Kaposi's sarcoma.
- Evidence of HIV infection as manifested by a positive antibody test.
Exclusion Criteria
- Active drug or alcohol abuse.
Co-existing Condition:
Excluded are patients with:
- Active opportunistic infections requiring ongoing therapy.
- Excluded within 90 days of study entry:
- Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.
- Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
- Concurrent neoplasms other than basal cell carcinoma of the skin.
- Known hypersensitivity to polymycin B or neomycin.
Excluded are patients with:
- Active opportunistic infections requiring ongoing therapy.
- Excluded within 90 days of study entry:
- Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.
- Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
- Concurrent neoplasms other than basal cell carcinoma of the skin.
- Known hypersensitivity to polymycin B or neomycin.
Prior Medication:
Excluded:
- Interferon.
- Zidovudine (AZT).
- Excluded within 30 days of study entry:
- Any biologic modifiers, corticosteroids, cytotoxic chemotherapeutic agents.
- Other drugs which can cause neutropenia or significant nephrotoxicity.
- Rifampin or rifampin derivatives, or systemic anti-infectives.
- Excluded within 90 days of study entry:
- Other antiviral agents.
- A history of Pneumocystis carinii pneumonia (PCP) completed treatment.
Prior Treatment:
Excluded within 30 days of study entry:
- Radiation therapy.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00000725
| United States, Florida | |
| Univ of Miami School of Medicine | |
| Miami, Florida, United States, 331361013 | |
| Study Chair: | Fischl MA |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000725 History of Changes |
| Other Study ID Numbers: |
ACTG 013 10989 ( Registry Identifier: DAIDS ES Registry Number ) |
| Study First Received: | November 2, 1999 |
| Last Updated: | March 15, 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Interferon Alfa-2a Sarcoma, Kaposi Dose-Response Relationship, Drug Drug Therapy, Combination |
Acquired Immunodeficiency Syndrome Zidovudine Interferon Type I |
Additional relevant MeSH terms:
|
HIV Infections Sarcoma Sarcoma, Kaposi AIDS-Related Opportunistic Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms |
Herpesviridae Infections DNA Virus Infections Neoplasms, Vascular Tissue Opportunistic Infections Infection Parasitic Diseases Interferons Interferon-alpha Zidovudine Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs Antimetabolites |
ClinicalTrials.gov processed this record on June 27, 2017